TG Therapeutics Inc logo

TG Therapeutics Inc

1
NAS:TGTX (USA)   Ordinary Shares
$ 21.00 -0.23 (-1.08%) 07:08 PM EST
95.45
P/B:
20.19
Volume:
1.54M
Avg Vol (2M):
2.51M
Trade In:
Volume:
1.54M
Avg Vol (2M):
2.51M

Business Description

TG Therapeutics Inc logo
TG Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US88322Q1085

Share Class Description:

TGTX: Ordinary Shares
Description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Name Current Vs Industry Vs History
Cash-To-Debt 1.88
Equity-to-Asset 0.43
Debt-to-Equity 0.7
Debt-to-EBITDA 2.07
Interest Coverage 4.01
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.6
Distress
Grey
Safe
Beneish M-Score 26.44
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 54.69
9-Day RSI 63.49
14-Day RSI 65.51
6-1 Month Momentum % 10.77
12-1 Month Momentum % -21.53

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.62
Quick Ratio 2.84
Cash Ratio 2.1
Days Inventory 813.47
Days Sales Outstanding 45.79

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.5
Shareholder Yield % -0.67

Financials (Next Earnings Date:2024-08-01 Est.)

TGTX's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:TGTX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

TG Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 289.334
EPS (TTM) ($) 0.22
Beta 2.28
Volatility % 101.03
14-Day RSI 65.51
14-Day ATR ($) 1.002406
20-Day SMA ($) 19.5705
12-1 Month Momentum % -21.53
52-Week Range ($) 6.46 - 23.12
Shares Outstanding (Mil) 154.54

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

TG Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

TG Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

TG Therapeutics Inc Frequently Asked Questions

What is TG Therapeutics Inc(TGTX)'s stock price today?
The current price of TGTX is $21.00. The 52 week high of TGTX is $23.12 and 52 week low is $6.46.
When is next earnings date of TG Therapeutics Inc(TGTX)?
The next earnings date of TG Therapeutics Inc(TGTX) is 2024-08-01 Est..
Does TG Therapeutics Inc(TGTX) pay dividends? If so, how much?
TG Therapeutics Inc(TGTX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1